SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma gains on getting USFDA approval for Voriconazole Tablets

26 May 2016 Evaluate

Ajanta Pharma is currently trading at Rs 1477.55, up by 3.20 points or 0.22% from its previous closing of Rs. 1474.35 on the BSE.

The scrip opened at Rs 1474.00 and has touched a high and low of Rs 1492.75 and Rs 1465.00 respectively. So far 5384 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720.00 on 12-Aug-2015 and a 52 week low of Rs. 1103.00 on 18-Jan-2016.

Last one week high and low of the scrip stood at Rs. 1580.75 and Rs. 1446.00 respectively. The current market cap of the company is Rs. 13039.70 crore.

The promoters holding in the company stood at 73.78% while Institutions and Non-Institutions held 11.67% and 14.55% respectively.

Ajanta Pharma has received final approval for Voriconazole Tablets (50mg & 200mg) from the US Food and Drug Administration (FDA). Voriconazole is a triazole antifungal for treatment of serious invasive fungal infections and the generic version of Vfend.

Voriconazole Tablets is part of ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US FDA has granted Ajanta Pharma 10 ANDA final approvals and 2 tentative approvals. An additional 14 ANDAs are under review with FDA.

Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.

Ajanta Pharma Share Price

3032.20 -48.00 (-1.56%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×